Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
...is this the cubes party line..
Sadly I never left.
...and now all of the sudden it is a strategic partnership
...my new handle might be EXACTKING
....on our way to BK.....
Definitely worth re-reading this writeup!
What is really interesting is the possibility of a T.F./Pluristem partnership to supply a multitude of biotechs with the basic infrastructure and technology to manufacture MSC products. This means Pluristem playing a role in the industry that goes way beyond their own individual path to approval for specific products. This could provide Pluristem with an income stream that bypasses the binary thumbs up/down in clinical trials, and thus de-risking the funding issue.
To minimize some of these existing gaps in processes and quality, the Israeli cell therapy firm has entered into a strategic partnership with bioprocessing vendor Thermo Fisher and hopes to address the industry as a whole rather than a specific therapy.
“The main goal of this partnership is to mutually develop solutions based on the knowledge accumulated in both companies in order to provide the market with better products, which will be able to support the growth required in the industry,” Yanay said.
Mr. (LMBOx200,000-196,000) is curious, VERY curious!
How close you make it to 200k shares?
(LMBOx200,000-196,000) and you don’t grasp the concept of DEAD MONEY. And no clue as to what a bucket shop is?
$1.15 today take it to the DEAD MONEY bank.
You invested within the last year and are losing money...BRILLIANT....
we have buffoons steering the ship.....
So PSTI is a bad investment is what you said.
PATHETIC
A compound??????
Janssen Sits On The ARM BoD With Zami
The bucket shop has fallen into a quagmire
TASE ends tomorrow at 415...the cratering will commence from here....DEAD MONEY
...watch for my next post which will predict where the TASE ends tomorrow
Yeah...the bozos got snookered in China
no one believes anything this company says.
DEAD MONEY.
Are you kidding?! Did you just learn this?! Wow, who would have imagined the immune system would be central.... Amazing.
Worthless....as usual. The original post I responded to said specifically "All biotechs make this claim"....and it is just not true.
The question implied that PSTI was the only company to say so and challenged anyone to name another. Zaatt named one. I found 3 others.
Critical thinking is not mandatory to post on this board...
Oh..Eichy..Your Words Are Dripping With Naiveté
your cube mate had to respond for you. PATHETIC...just like PSTI
Unduly pessimistic, AGAIN and AGAIN! LOL!
suspect that a substantial order for this product will occur prior to the approval of any other product that could produce a revenue flow
So..., "AutoEich" has once more shown that when you run out of steam, try deception (doesn't work, too many intelligent investors here)!
Thanks PLX-11 !
Eich demands proof, PLX-11 generously provides it:
Show us examples of biotech's that state “we don’t know when we will be profitable, if ever” in their 10-k.
.Lord knows the company doesn't make any money....or anything.
Show us examples of biotech's that state “we don’t know when we will be profitable, if ever” in their 10-k
$1.18....I said $1.19 on Monday......and again today even after the "Good News" PR....What a complete joke.
.....PSTI is headed for BK
Nah, 4.5 years to get to Phase III is far too long.
If there was any validity to the science it would not be $1.20
blood sucking lawyer Ken keeps stealing our money
quite the turnaround this morning from 1.13 to 1.25 nice!
Based on our results of a reduction of postoperative stress by PLX-PAD, the indication has been adapted to hip fracture patients, who suffer even more due to the surgery-induced stress of hip arthroplasty. In addition, we included in the Phase III study endpoints which measure the systemic effect of PLX-PAD, which we observed in the earlier study, such as increase of contralateral gluteal muscle force and pro-regenerative immunological changes.
Taken together, we believe the Phase III study design greatly supports the likelihood of its success
LOL! BINGO! Thanks midas! EOM.
While not always agreeing with FDA, I like many on this board appreciate the information and updates he provides.